Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Felix HoferNiema KazemRonny SchweitzerAndreas HammerFriedrich JakseLorenz KollerChristian HengstenbergPatrick SulzgruberAlexander NiessnerPublished in: Cardiovascular drugs and therapy (2021)
The present analysis revealed an infrequent prescription of SGLT2i and GLP-1RAs in patients with T2DM and CAD in clinical practice. Remuneration regulations that better reflect the inclusion criteria of the CV outcome trials would allow more patients at high risk to receive these CV protective drugs. Most importantly, while GLP-1RA therapy showed a trend for risk reduction of cardiovascular mortality, the use of SGLT2i had a strong inverse impact on cardiovascular mortality from a long-term perspective.
Keyphrases
- end stage renal disease
- clinical practice
- ejection fraction
- newly diagnosed
- coronary artery disease
- chronic kidney disease
- rheumatoid arthritis
- risk factors
- cardiovascular disease
- systemic lupus erythematosus
- bone marrow
- insulin resistance
- mesenchymal stem cells
- drug induced
- smoking cessation
- idiopathic pulmonary fibrosis
- chemotherapy induced